glyceryl-behenate and Lymphoma

glyceryl-behenate has been researched along with Lymphoma* in 1 studies

Other Studies

1 other study(ies) available for glyceryl-behenate and Lymphoma

Article	Year
Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (London, England), 2012, Volume: 7, Issue:5 Lipid nanoparticles (LNs) made of synthetic lipids Compritol(®) 888 ATO and Precirol(®) ATO 5 were developed with an average size of 110.4 ± 2.1 and 103.1 ± 2.9 nm, and an encapsulation efficiency above 85% for both type of lipids. These LNs decrease the hemolytic toxicity of the drug by 90%.. Pharmacokinetic and biodistribution profiles of the drug were studied after intravenous and oral administration of edelfosine-containing LNs.. This provided an increase in relative oral bioavailability of 1500% after a single oral administration of drug-loaded LNs, maintaining edelfosine plasma levels over 7 days in contrast to a single oral administration of edelfosine solution, which presented a relative oral bioavailability of 10%. Moreover, edelfosine-loaded LNs showed a high accumulation of the drug in lymph nodes and resulted in slower tumor growth than the free drug in a murine lymphoma xenograft model, as well as potent extranodal dissemination inhibition. Topics: Animals; Diglycerides; Fatty Acids; Humans; Leukemic Infiltration; Lymph Nodes; Lymphoma; Mice; Nanoparticles; Neoplasms, Experimental; Phospholipid Ethers	2012

Article

Year

Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles.

Nanomedicine (London, England), 2012, Volume: 7, Issue:5

Lipid nanoparticles (LNs) made of synthetic lipids Compritol(®) 888 ATO and Precirol(®) ATO 5 were developed with an average size of 110.4 ± 2.1 and 103.1 ± 2.9 nm, and an encapsulation efficiency above 85% for both type of lipids. These LNs decrease the hemolytic toxicity of the drug by 90%.. Pharmacokinetic and biodistribution profiles of the drug were studied after intravenous and oral administration of edelfosine-containing LNs.. This provided an increase in relative oral bioavailability of 1500% after a single oral administration of drug-loaded LNs, maintaining edelfosine plasma levels over 7 days in contrast to a single oral administration of edelfosine solution, which presented a relative oral bioavailability of 10%. Moreover, edelfosine-loaded LNs showed a high accumulation of the drug in lymph nodes and resulted in slower tumor growth than the free drug in a murine lymphoma xenograft model, as well as potent extranodal dissemination inhibition.

Topics: Animals; Diglycerides; Fatty Acids; Humans; Leukemic Infiltration; Lymph Nodes; Lymphoma; Mice; Nanoparticles; Neoplasms, Experimental; Phospholipid Ethers

2012